Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: A retrospective study

Clinical and Translational Oncology

Volumn 11, Issue 11, 2009, Pages 748-752

  Alonso, Lorenzo ^a   Gallego, Elena ^a   González, Francisco Jesús ^b   Sánchez Muñoz, Alfonso ^a   Torres, Esperanza ^a   Pajares, Bella Isabel ^a   Leeflang, Stephanie ^a   Baha, Camelia ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Hospital University Carlos Haya de Málaga   (Spain)

Author keywords

Gonadotropin releasing hormone receptor; Oestrogen receptor; Ovarian cancer; Prognostic factor

Indexed keywords

CARBOPLATIN; ESTROGEN RECEPTOR; GESTAGEN; GONADORELIN; GONADORELIN RECEPTOR; GONADOTROPIN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GONADOTROPINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, LHRH; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; RETROSPECTIVE STUDIES;

EID: 73449132226     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0437-4     Document Type: Article

References (34)

1. M.J. Piccart K. Bertelsen K. James, et al. 2000 Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 699 708 10.1093/jnci/92.9.699 1:CAS:528:DC%2BD3cXjslSns7c%3D 10793106
2. W.P. McGuire W.J. Hoskins M.F. Brady, et al. 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 6 10.1056/NEJM199601043340101 1:CAS:528:DyaK28XhtFKiur4%3D 7494563 (Pubitemid 26012496)
3. R.F. Ozols B.N. Bundy B.E. Greer, et al. 2003 Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 3194 3200 10.1200/JCO.2003.02.153 1:CAS:528: DC%2BD2cXps1aktbk%3D 12860964 (Pubitemid 46606249)
4. R.E. Bristow R.S. Tomacruz D.K. Armstrong, et al. 2002 Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis Clin Oncol 20 1248 1259 10.1200/JCO.20.5.1248 (Pubitemid 34177431)
5. W.J. Hoskins B.N. Bundy J.T. Thigpen, et al. 1992 The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 159 166 10.1016/0090-8258(92)90100-W 1:STN:280:DyaK3s7gs1Cqsw%3D%3D 1468693 (Pubitemid 23001322)
6. W.J. Hoskins W.P. McGuire M.F. Brady, et al. 1994 The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 974 980 1:STN:280:DyaK2c3hvFGntQ%3D%3D 8166218
7. T. Riman P.W. Dickman S. Nilsson, et al. 2002 Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women J Natl Cancer Inst 94 497 504 1:CAS:528:DC%2BD38Xjt1Ciur4%3D 11929950 (Pubitemid 34411288)
8. A.R. Folsom J.P. Anderson J.A. Ross 2004 Estrogen replacement therapy and ovarian cancer Epidemiology 15 100 104 10.1097/01.ede.0000091606.31903.8e 14712153 (Pubitemid 40417003)
9. T. Riman P.W. Dickman S. Nilsson, et al. 2002 Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study Am J Epidemiol 156 363 373 10.1093/aje/kwf048 12181107 (Pubitemid 34858005)
10. A.S. Sit F. Modugno J.L. Weissfeld, et al. 2002 Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma Gynecol Oncol 86 118 123 10.1006/gyno.2002.6746 1:CAS:528:DC%2BD38XlsFKgtLc%3D 12144815 (Pubitemid 34953491)
11. P.C. Leung C.K. Cheng X.M. Zhu 2003 Multi-factorial role of GnRH-I and GnRH-II in the human ovaries Mol Cell Endocrinol 202 145 153 1:CAS:528:DC%2BD3sXktFSnsbk%3D 12770744
12. T. Minegishi T. Kameda T. Hirakawa, et al. 2000 Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms Clin Cancer Res 6 2764 2770 1:CAS:528:DC%2BD3cXlslentL0%3D 10914722
13. T. Furui A. Imai T. Tamaya 2002 Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers Oncol Rep 9 349 352 1:CAS:528:DC%2BD38XitVCgsLY%3D 11836606
14. I. Konishi H. Kuroda M. Mandai 1999 Review: gonadotropin and development of ovarian cancer Oncology 57 [Suppl2] 45 48 10.1159/000055274 1:CAS:528:DyaK1MXntVGht7o%3D 10545802 (Pubitemid 29494884)
15. B.A. Du W. Meier H.J. Luck, et al. 2002 Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer Ann Oncol 13 251 257 10.1093/annonc/mdf038 11886002
16. L. Paskeviciute H. Roed A. Engelholm 2002 No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer Eur J Cancer 138 [Suppl6] S73 10.1016/S0959-8049(02)00295-2
17. G. Balbi L.D. Piano A. Cardone, et al. 2004 Second-line therapy of advanced ovarian cancer with GnRH analogs Int J Gynecol Cancer 14 799 803 10.1111/j.1048-891X.2004.014511.x 1:STN:280:DC%2BD2cvlt1KmsQ%3D%3D 15361187 (Pubitemid 39238163)
18. J.L. Perez-Gracia E.M. Carrasco 2002 Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research Gynecol Oncol 84 201 209 10.1006/gyno.2001.6489 1:CAS:528:DC%2BD38Xntlyhug%3D%3D 11812075 (Pubitemid 34139799)
19. A. Bowman H. Gabra S.P. Langdon, et al. 2002 CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup Clin Cancer Res 8 2233 2239 1:CAS:528:DC%2BD38XmtVWhsrg%3D 12114425
20. C.A. Papadimitriou S. Markaki J. Siapkaras, et al. 2004 Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study Oncology 66 112 117 10.1159/000077436 1:CAS:528: DC%2BD2cXjvVCitr8%3D 15138362 (Pubitemid 38608377)
21. G. Walker K. MacLeod A.R.W. Williams, et al. 2007 Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer Clin Cancer Res 13 1438 1444 10.1158/1078-0432.CCR-06-2245 1:CAS:528:DC%2BD2sXitlSjtrY%3D 17332286 (Pubitemid 46450433)
22. P. Lindgren T. Bäckström C.G. Mählck, et al. 2001 Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors Int J Oncol 19 31 38 1:CAS:528:DC%2BD3MXltFeju7w%3D 11408919
23. P. Lee D.G. Rosen C. Zhu, et al. 2005 Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer Gynecol Oncol 96 671 677 10.1016/j.ygyno.2004.11.010 1:CAS:528:DC%2BD2MXhsVOjsrs%3D 15721410 (Pubitemid 40255486)
24. P. Völker C. Gründker O. Schmidt 2002 Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues Am J Obstet Gynecol 186 171 179 10.1067/mob.2002.119633 11854630 (Pubitemid 34165428)
25. A. Imai T. Ohno K. Lida, et al. 1994 Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types Cancer 74 2555 2561 10.1002/1097-0142(19941101)74:9<2555::AID- CNCR2820740925>3.0.CO;2-X 1:STN:280:DyaK2M%2FgsleqtQ%3D%3D 7522953 (Pubitemid 24320862)
26. W.J. Hoskins B. Bundy J.T. Thigpen, et al. 1992 The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 159 166 10.1016/0090-8258(92)90100-W 1:STN:280:DyaK3s7gs1Cqsw%3D%3D 1468693 (Pubitemid 23001322)
27. J. Fujimoto S.M. Alam I. Jahan, et al. 2007 Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers J Steroid Biochem Mol Biol 104 301 304 10.1016/j.jsbmb.2007.03.016 1:CAS:528:DC%2BD2sXmsFKnsbY%3D 17509876 (Pubitemid 46891819)
28. K. Münstedt J. Steen A.G. Knauf, et al. 2000 Steroid hormone receptors and long term survival in invasive ovarian cancer Cancer 89 1783 1791 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D 11042574 (Pubitemid 30794173)
29. E.V. Hogdall L. Christensen C.K. Hogdall, et al. 2007 Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study Oncol Rep 18 1051 1059 17914554
30. H. Arias-Pulido H.O. Smith N.E. Joste, et al. 2009 Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors Gynecol Oncol 114 480 485 10.1016/j.ygyno.2009.05.045 1:CAS:528:DC%2BD1MXptlSrt7g%3D 19560192
31. M.A. Bookman 2005 Is there still a role for hormonal therapy? Int J Gynecol Cancer 15 [Suppl3] 291 297 10.1111/j.1525-1438.2005.00442.x 16343246 (Pubitemid 43096596)
32. Y.F. Li W. Hu S.Q. Fu, et al. 2008 Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer 18 600 614 10.1111/j.1525-1438. 2007.01075.x 1:STN:280:DC%2BD1crisl2itg%3D%3D 17894799 (Pubitemid 352020164)
33. C.T. Brekelmans C. Seynaeve M. Menke-Pluymers, et al. 2006 Survival and prognostic factors in BRCA1-associated breast cancer Ann Oncol 17 391 400 10.1093/annonc/mdj095 1:STN:280:DC%2BD287ht1OksQ%3D%3D 16322115 (Pubitemid 43329574)
34. A. Chetrit G. Hirsh-Yechezkel Y. Ben-David, et al. 2008 Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 20 25 10.1200/JCO.2007.11.6905 18165636